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With the advent of novel strategies to induce tolerance in autoimmune and autoim-
mune-like conditions, clinical trials of antigen-specific tolerizing immunotherapy have 
become a reality. Besides safety, it will be essential to gather mechanistic data on 
responding CD4+ T cells to assess the effects of various immunomodulatory approaches 
in early-phase trials. Peptide–MHC class II (pMHCII) multimers are an ideal tool for 
monitoring antigen-specific CD4+ T  cell responses in unmanipulated cells directly ex 
vivo. Various protocols have been published but there are reagent and assay limitations 
across laboratories that could hinder their global application to immune monitoring. 
In this methodological analysis, we compare protocols and test available reagents to 
identify sources of variability and to determine the limitations of the tetramer binding 
assay. We describe a robust pMHCII flow cytometry-based assay to quantify and phe-
notype antigen-specific CD4+ T cells directly ex vivo from frozen peripheral blood mono-
nuclear cell samples, which we suggest should be tested across various laboratories to 
standardize immune-monitoring results.
Keywords: antigen-specific t cells, tetramers, tetramerization, protocol standardization, flow cytometry
INtRodUCtIoN
Autoimmune diseases result from chronic T cell and B cell autoimmune responses leading to tissue 
inflammation and damage. Helper CD4+ T cells play a central role in autoimmune responses because 
they orchestrate the function of other immune cells including cytotoxic T cells and B cells. Current 
treatment strategies for autoimmune diseases target inflammation, the whole immune system, or the 
total T cell or B cell populations, modulating the immune response in antigen non-specific approaches. 
Antigen-specific tolerizing immunotherapy specifically targets the autoimmune response leaving 
the rest of the immune system unimpaired. Several different approaches to induce antigen-specific 
tolerance have been developed over recent years, and the first clinical trials are completed and are 
in progress (1, 2). These immunomodulatory approaches require the development of tools to assess 
the efficacy of antigen-specific tolerizing immunotherapy. To monitor antigen-specific CD4+ T cell 
responses, antigen-specific CD4+ T cells can be restimulated with peptide ex vivo for analysis of 
proliferation and cytokine production. However, responses to autoantigenic peptides in human 
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PB are typically much lower and more variable than in mouse 
models of autoimmune disease. Autoantibody titers provide an 
indirect measure of CD4+ autoreactive T  cell function. Such 
assays are robust and often already standardized and available as 
qualified assays in clinical laboratories. In recent years, peptide–
MHC class II (pMHCII) multimers have emerged as a tool for 
analysis of antigen reactive, including autoreactive CD4+ T cells 
in blood or other accessible tissue sites directly ex vivo or after a 
period of in vitro restimulation with peptide (3–6). They consist 
of biotinylated MHC class II molecules with bound peptide 
multimerized with fluorochrome-labeled streptavidin (7). The 
peptide presented by the MHC class II molecule is the self- or 
autoantigen that is targeted by the tolerizing immunotherapy. 
Hence, antigen-specific T cell receptors (TCRs) on CD4+ T cells 
can be detected in flow cytometric assays to enumerate the 
number and, with cell surface-specific monoclonal antibodies, 
the phenotype of antigen-specific CD4+ T  cells restricted to a 
particular MHC class II molecule.
Various protocols on the use of pMHCI and pMHCII tetram-
ers and surface antibody staining to enumerate and phenotype 
unmanipulated cells directly ex vivo or in vitro peptide-stimulated 
T  cells have been published in recent years (8–10). However, 
autoantigen-specific CD4+ T cells are rare in the circulation (gen-
erally less than 100/106 CD4 T cells), the TCR is of low affinity and 
the pMHCII have a high off-rate (3, 11, 12), thus optimization of 
staining for consistent identification of TCR reactive with pMH-
CII is technically challenging. Several methodologies have been 
described to enhance detection, including staining cells with 
tetramers labeled with phycoerythrin (PE)-based fluorochromes 
followed by enrichment using PE-beads and magnetic-activated 
cell sorting (13). Alternative published approaches include the 
tyrosine kinase inhibitor dasatinib, to reduce TCR internaliza-
tion and maximize TCR surface detection, and amplification of 
the tetramer signal using an antibody sandwich (7, 8, 14). There 
are also various options for the procurement or generation of 
multimer reagents, including specialized research laboratories, 
the NIH tetramer core facility, and several commercial suppliers, 
including MBL, ProImmune (PI), and Immudex.
In this methodological analysis, we compared several appro-
aches to the staining of antigen-specific CD4+ T  cells using 
PE-labeled tetramers directly ex vivo and tested reagents from two 
commercial suppliers and one specialized research laboratory 
to identify sources of variability and limitations of the assay. We 
optimized a pMHCII tetramer flow cytometry-based protocol to 
quantify and phenotype unmanipulated antigen-specific CD4+ 
T cells in the circulation of individuals to enable the visualization 
of cellular changes in vivo.
Methods
Patient samples
Peripheral blood mononuclear cells (PBMC) were isolated from 
PB of rheumatoid arthritis (RA) patients visiting the outpatient 
clinic of the Princess Alexandra Hospital in Brisbane, Australia. 
The protocol was approved by the Metro South and UQ HRECs, 
and informed consent was obtained from all participants.
pMhCII tetramers
HLA-DRB1*0401 or HLA-DRB1*0101 hemagglutinin306–318 and 
collagen type II259–273 monomers were generated as previously 
described (14) and tetramerized using streptavidin-PE (BD 
Biosciences) or purchased either as monomers or tetramers from 
commercial suppliers (PI and MBL).
Monoclonal Antibodies
The following monoclonal antibodies were used in this study: 
antihuman CD3 evolve™ 655 (eBioscience), antihuman CD3 
BUV737 (BD Biosciences), antihuman CD4 BUV395 (BD 
Biosciences), antihuman CD4 PerCP/efluor710 (eBioscience), 
antihuman CD4 AlexaFluor 700 (BD Biosciences), antihuman 
CD11c FITC (BioLegend), antihuman CD14 FITC (BioLegend), 
antihuman CD16 FITC (BioLegend), and antihuman CD19 FITC 
(BioLegend).
Flow Cytometric Analysis
Peripheral blood mononuclear cells were either stained directly 
after isolation or after storage in liquid nitrogen. Frozen PBMCs 
were thawed in RPMI [in the presence of 12.5  µg/ml DNase I 
(Sigma) until the first centrifugation step and with 6.25  µg/ml 
DNase I until the second centrifugation step]. Thawed cells were 
rested in a 37°C incubator for 15–20 min, with clumps of dead 
cells subsequently removed using a cell strainer (Corning). To 
prevent non-specific binding, FcR Blocking reagent (Miltenyi 
Biotech) was used according to the manufacturer’s protocol (2 µl 
up to 10 million cells). When a dasatinib step was included during 
the staining procedure, cells were incubated with 50 nM dasatinib 
(Selleck Chemicals) in RPMI containing 10% human AB serum, 
50 U/ml IL-2 and 25 mM glucose in a 37°C waterbath for 30 min. 
Tetramer was then added at a concentration of 4.2 μg/ml and 
incubated for 1  h at 4°C. The cells were then washed once in 
FACS Buffer (0.1% BSA and 2 mM EDTA in PBS) and incubated 
with a mix of surface antibodies. Where sandwich staining was 
included, cells were stained with anti-PE biotin (BioLegend) at 
1:1,000 or rabbit anti-PE (MyBiosource) at 1:4,000 for 20 min at 
4°C after the tetramer staining. Subsequently cells were washed 
once in 1× FACS Buffer and incubated together with surface 
antibodies and streptavidin-PE (BD Biosciences) at 1:1,000 or 
AlexaFluor 555 goat anti-rabbit (Life Technologies) for 20 min 
at 4°C. To discriminate live from dead cells, cells were washed in 
PBS and stained using the LIVE/DEAD fixable Dead Cell Stain Kit 
(Invitrogen) according to the manufacturer’s protocol. All sam-
ples were acquired on a BD LSR Fortessa X20 (BD Biosciences).
ResULts
the Numbers of pMhCII tetramer-Positive 
Cells Were Comparable in Frozen and 
Freshly Isolated Cell samples
In clinical trials, PBMC samples are normally collected at several 
time points to monitor mechanism or efficacy of treatment. To 
internally control for experimental variation, PBMC collected 
from a single donor at different time points are ideally frozen, 
then thawed, stained and analyzed using an internally controlled, 
tAbLe 1 | Overview number of detected collagen II-specific CD4+ T cell in fresh and frozen samples.
donor tetramer employed # tetramer+ cells/106 Cd4+ 
t cells, fresh
# tetramer+ cells/106 
Cd4+ t cells, frozen
# tetramer+ cells/106 
Cd4+ Cd4+ t cells, fresh+ 
sandwich
# tetramer+ cells/106 
Cd4+ Cd4+ t cells, 
frozen+ sandwich
1 HLA-DRB1*01:01-collagen II259–273 54.36 53.44
2 HLA-DRB1*01:01-collagen II259–273 141.19 47.27
3 HLA-DRB1*04:01-collagen II259–273 25.59 66.70 80.64 108.64
4 HLA-DRB1*04:01-collagen II259–273 55.82 20.05 56.72 55.81
5 HLA-DRB1*01:01-collagen II259–273 1.26 12.51
6 HLA-DRB1*01:01-collagen II259–273 12.85 10.61
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qualified assay. Collagen II259–273 is the dominant epitope in the 
murine collagen-induced arthritis model in HLA-DRB1*04:01 
or HLA-DRB1*01:01 transgenic mice and the collagen II259–273 
specific TCR repertoire in these mice is highly restricted (15). 
A functional T cell stimulation assay identified T cells respond-
ing to the same epitope in HLA-DRB1*04:01+ RA patients and 
healthy controls (16). Furthermore, the dominant influenza 
epitope HA306–318 can be presented by both HLA-DRB1*04:01 
and HLA-DRB1*01:01 (17). HLA-DRB1*04:01-HA306–318 tetram-
ers were shown to identify antigen-specific T cells in RA patients 
(14, 18). Thus, HA-specific CD4+ T  cells represent an internal 
control for tetramer staining, independent of RA.
We first tested variability in the capacity to detect CD4+ 
antigen-specific T cells from RA patients from freshly isolated 
or frozen PBMC using a published pMHCII tetramer-staining 
protocol (7, 14). We generated tetramers specific for HLA-
DRB1*04:01-collagen II259–273, HLA-DRB1*01:01-collagen II259–
273, HLA-DRB1*04:01-HA306–318, and HLA-DRB1*01:01-HA306–318 
and assessed antigen-specific CD4+ T cells in patients with an 
appropriate HLA type. In the first set of experiments, we endeav-
ored to increase tetramer detection sensitivity by incubation 
with dasatinib and secondary antibody sandwich. Dasatinib is a 
tyrosine kinase inhibitor, which prevents internalization of the 
TCR and therefore increases the number of cell surface TCRs 
that can bind the tetramer and hence the detection signal. In 
some experiments, we included a sandwich step of biotinylated 
anti-PE antibody followed by streptavidin-PE or rabbit anti-PE 
followed by goat anti-rabbit AlexaFluor 555 to amplify the 
signal (7).
Fresh samples from RA patients were collected and stained 
immediately or frozen. Frozen cells were thawed and stained 
3–8 days later with HLA-DRB1*04:01-collagen II259–273 or HLA-
DRB1*01:01-collagen II259–273 tetramers. Collagen II-specific 
CD4+ T  cells were detected in both fresh and frozen samples 
(Table 1). There was no consistent increase or decrease in tetramer 
frequency in frozen and thawed cells relative to freshly isolated 
cells from the same donor. Furthermore, in the two patients in 
which the sandwich step was included, the tetramer frequency 
was the same or increased relative to samples stained without 
sandwich amplification (Table 1). These results indicate that while 
frozen samples can be used for the detection of antigen-specific 
CD4+ T cells using pMHCII tetramers with or without sandwich 
amplification, the frequency of autoantigen-specific cells can vary 
from assay to assay in the same patient.
A shorter staining Process Resulted in 
higher Yield of Cells for Analysis
PBMC, including activated PB T  cells, from RA patients are 
fragile and have a high propensity for apoptosis in culture, which 
is amplified after thawing. Furthermore, we and others have 
shown that CD4+ tetramer+ T  cells include activated memory 
T cells (6, 14, 18), which are particularly sensitive to manipula-
tion in vitro. Given the variability in tetramer+ cells from assay 
to assay, and our observations that cell death occurred during 
the prolonged staining procedure required for dasatinib, sand-
wich amplification and multiple washes (“long protocol”), we 
developed an alternative protocol with minimal cell handling, 
i.e., short tetramer incubation step at 4°C, followed by addition 
of cell surface antibodies without washing in between (“short 
protocol”). We compared the two protocols directly in HLA-
DRB1*01:01+ RA patients using HLA-DRB1*01:01-HA306–318 
and HLA-DRB1*01:01-collagen II259–273 tetramers. The number 
of HLA-DRB1*01:01-HA306–318-specific cells was fourfold higher 
using the short protocol than the long protocol (Figure  1A). 
Where these protocols were compared head to head in two 
further patients, the number of HLA-DRB1*01:01-collagen 
II259–273-specific cells was twofold higher using the short protocol 
than the long protocol (Figures  1B,C; Table  2). We therefore 
compared cell yields and frequency of tetramer+ cells across 20 
HLA-DRB1*04:01+ or *01:01+ frozen PBMC from RA donors, 
10 of which were stained with the long protocol and 10 with the 
short protocol (Table 3). For the long protocol, the number of 
PBMC included per tetramer stain was 3–18 × 106 cells, all of 
which had to be acquired on the flow cytometer to achieve suf-
ficient frequency of tetramer+ CD3+ CD4+ T cells (mean 0.002%). 
By contrast, for the short protocol ≤5 × 106 PBMC were included 
per tetramer stain, and of these, acquisition of 1–2 ×  106 cells 
(mean 1.42 ×  106, which did not use the entire tube of cells) 
was sufficient to achieve an improved frequency of tetramer+ 
CD3+ CD4+ T cells (mean 0.012%). Thus, the short protocol not 
only increased the yield of PBMC that could be acquired on the 
flow cytometer for analysis but also increased the efficiency of 
detection of tetramer+ cells without any increase in background 
staining in the FMO control (Figure 1). As a result, the number 
of cells required for acquisition dropped to 1–2 × 106 cells, which 
greatly decreased acquisition time and thus reduced assay cost. 
These data indicate that shorter processing time without wash 
steps reduces loss of cells during processing, preserves viability, 
and increases tetramer+ T cell detection efficiency.
FIgURe 1 | Shorter staining protocol resulted in higher numbers of tetramer-positive CD4+ T cells. Three staining protocols were compared as indicated. (A) The 
number of HLA-DRB1*0101 HA306–318-positive CD4+ T cells per million CD4+ T cells is depicted for the three protocols in peripheral blood mononuclear cells of one 
representative individual. (b) Flow cytometry plots for two patients stained with HLA-DRB1*0101-collagen II259–273, using either the short or the long protocol. The 
negative control FMO plots are shown. (C) The number of HLA-DRB1*0101-collagen II259–273+ CD4+ T cells per million CD4+ T cells using the short versus the long 
staining protocol in Donors A and B, as depicted in panel (b).
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overcoming Challenges of Cell  
Yield after thawing
Given that viability appears to be critical for identification of 
antigen-specific CD4+ T  cells in RA PB, we compared differ-
ent approaches to minimize the cell loss after thawing and to 
maximize the yield of cells for analysis of antigen-specific CD4+ 
T cells. First, we noted that after addition of DNase during the 
thawing process, free-floating DNA fragments and cell clump 
formation were minimized, increasing yield of cells in suspen-
sion. Second, resting thawed cells at 37°C for 20  min allowed 
cells to recover, and cell clumps could be removed from the cell 
suspension before staining, preventing clump formation during 
staining. We observed that clumps forming during staining are 
difficult to remove, often resulting in a further loss of cells. Third, 
tAbLe 3 | Identification of tetramer+ cells after short and long staining protocols.
hLA-dRb1* Protocol # Cells  
stained × 10−6
# Cells  
acquired × 10−6
% gated live Cd3+  
Cd4+ cells*
% Live tetramer+ Cd3+  
Cd4+ cells
# tetramer+/106 Cd3+  
Cd4+ cells
04:01 Long 17 4.1 55.8 0.0029 52.9
04:01 Long 9 2.3 49.4 0.0019 39.8
04:01/01:01 Long 9 3.2 74.5 0.0005 7.32
04:01 Long 14 5.0 61.8 0.0038 62.5
04:01 Long 13 5.1 68.5 0.0016 23.3
04:01 Long 15 4.3 78.1 0.0013 16.4
04:01 Long 3.2 1.4 71.0 0.0056 79.5
04:01 Long 7.5 2.1 71.2 0.0024 32.7
04:01 Long 7 2.9 51.5 0.0017 33.1
Mean (SD) 10.5 (4.5) 3.4 (1.3) 64.6 (10.4) 0.0024 (0.002) 38.6 (23.0)
04:01 Short 5 1.2 71.9 0.0208 289
01:01 Short 5 1.5 77.6 0.0165 213
04:01 Short 5 1.4 71.3 0.0176 248
01:01 Short 5 2.0 72.7 0.0279 384
04:01 Short 3 1.6 70.2 0.0074 106
01:01 Short 3 1.9 76.3 0.0146 191
01:01 Short 3 1.0 51.1 0.0064 126
04:01 Short 3 1.0 63.1 0.0077 123
04:01 Short 2 1.2 75.2 0.0029 38
01:01 Short 2 1.4 51.8 0.0023 44
Mean (SD) 3.6 (1.3) 1.4 (0.3) 68.1 (9.6) 0.0124 (0.008) 176 (110)
Peripheral blood mononuclear cells from 20 rheumatoid arthritis donors were stained with collagen II257–273 tetramers according to HLA-DRB1* type (column 1) using the long or the 
short protocols. The number of cells stained and acquired as well as the percentage (%) and number (#) of tetramer+ T cells are shown. Whereas all cells stained were subsequently 
acquired for the long protocol, in the short protocol 1–2 × 106 cells were collected per sample. * for the long protocol, CD3+ CD4+ T cells were gated based on exclusion of FITC+ 
lineage− dump channel in combination with Aqua+ live/dead discriminator. For the short protocol, green live/dead discriminator was included in the FITC dump channel, which was 
used for exclusion.
NA, not available.
tAbLe 2 | Recovery and identification of tetramer+ cells after short and long staining protocols.
Figure Protocol # Cells 
stained × 106
# Cells 
acquired × 106
% Live Cd3+ 
Cd4+ cells
% Live tetramer+ Cd3+ 
Cd4+ cells
Fold increase over 
long protocol
# tetramer+/106 
Cd3+ Cd4+ cells
1A Long 2 1.04 NA 0.0048 128
Short + wash 2 0.82 NA 0.0076 1.6 55
Short − wash 2 0.9 NA 0.0140 2.9 413
1B Donor A Long 2.5 0.8 40.1 0.0051 17
Short 2.5 0.95 24.7 0.0104 2 58
Donor B Long 2.5 1.1 57.0 0.0256 449
Short 2.5 1.3 58.3 0.0447 1.74 783
In the first experiment (Figure 1A), 2 × 106 peripheral blood mononuclear cells were stained per protocol, and in the second (Figure 1B) 2.5 × 106 cells were stained per protocol 
for each of 2 donors. The percentage (%) live tetramer+ CD3+ CD4+ T cells identified using the long protocol was improved twofold to threefold by use of the short protocol without 
washes.
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as noted earlier, cells are lost with every wash step, and reducing 
the number of wash steps increased cell yield (Table 2; Figure 1).
tetramers from different sources  
Result in staining Variability
For a clinical trial, monomers or tetramers qualified by a com-
mercial supplier are preferred to research reagents. To test 
variability between reagents we compared staining with custom 
HLA-DRB1*04:01-collagen II259–273 and HLA-DRB1*01:01-
collagen II259–273 tetramers purchased from two commercial 
suppliers, MBL and PI, with research tetramers produced as 
previously described (14). Cells were stained according to the 
manufacturer’s protocol, which was very similar to the short 
protocol described earlier except that PI and MBL recommended 
staining cells with tetramer for 2 h at 37°C. Since the above tests 
using research tetramers were optimized at 4°C, we compared 
the manufacturer’s protocol staining cells with tetramers for 2 h 
at 37°C with our protocol staining cells with tetramers at 4°C for 
1 h. Compared with the FMO and research tetramers, the com-
mercial tetramers had an overall spreading of the CD3+ CD4+ 
tetramer-negative PE signal and a reduction in fluorescence 
intensity of the cloud of HLA-DRB1*04:01-collagen II259–273+ 
T cells (Figure 2A). Staining at 37°C increased cell clumping and 
reduced tetramer staining using either research or MBL tetram-
ers. HLA-DRB1*01:01-collagen II259–273 T  cells were virtually 
undetectable when staining with MBL tetramers (Figure 2B).
Commercially supplied tetramers have been tetramerized from 
biotinylated monomers using undisclosed methodology and rea-
gents, and a volume/test rather than concentration is provided by 
6Jansen et al. pMHCII Tetramers: Methods and Protocol
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FIgURe 2 | Continued
FIgURe 2 | The streptavidin–biotin ratio is important for optimal tetramer formation. Research tetramers were compared with tetramers purchased from MBL and 
ProImmune (PI). (A) Flow cytometry plots of a representative donor depicting FMO-PE and staining with HLA-DRB1*0401-collagen II259–273 tetramers using the short 
staining protocol (representative of three HLA-DRB1*04:01+ and three HLA-DRB1*01:01+ donors with rheumatoid arthritis). (b) The number of tetramer-positive cells 
per million CD4+ T cells identified using HLA-DRB1*0401-collagen II259–273 and HLA-DRB1*0101-collagen II259–273 tetramers from two sources (n = 3 replicates per 
donor), staining at 4°C. (C) Flow cytometry dot plots depicting the number of tetramer-positive cells using tetramers generated from monomers as depicted, from 
two sources using the same formula to calculate the streptavidin–biotin ratio and each stained at a concentration of 4.2 µg/ml (representative of three individual 
donors). In panels (A,b), staining with research and MBL tetramers was carried out at 4 and 37°C and with PI tetramers at 37°C. In panel (C), all tetramers were 
stained at 4°C.
tAbLe 4 | Formula for streptavidin-PE volume calculation for tetramerization of 
biotinylated monomers.
Volume Strep-PE to add 10 times (μl) = ((amount monomer 
(μg) × 0.74285714285714)/8)/5
Volume monomer needed = amount monomer (μg)/concentration biotin (mg/ml)
Concentration biotin = concentration monomer × percentage biotinylation
The rationale is as follows: Mass of biotinylated monomer used/70,000 (Mw of Class II 
HLA-DR) = Volume of Strep-PE/52,000 (Mw of Strep-PE) × 8 (1:8 ratio of Strep-PE to 
biotinylated monomer needed) × 0.5 (concentration Strep-PE in mg/ml).
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the manufacturer. The observed difference in PE signal between 
research and commercial tetramers suggested differences in 
staining may be related to the streptavidin–biotin ratio used for 
tetramerization and/or tetramer concentration when staining. 
To be able to standardize across comparisons, we purchased 
DRB1*04:01-collagen II259–273 and HLA-DRB1*01:01-collagen 
II259–273 biotinylated monomers from MBL, requested details of % 
biotinylation and monomer concentration and tetramerized each, 
based on the percentage of monomer biotinylation according to 
the formula in Table 4. The resulting tetramers generated in our 
laboratory from MBL or research biotinylated monomers gave 
comparable staining on the same patient cell samples (Figure 2C) 
when stained at 4.2 µg/ml at 4°C. These results indicate that for 
optimal reproducibility between tetramer production facilities 
and laboratories receiving different batches of tetramers, it is 
important to standardize the procedures for tetramerization 
from biotinylated monomers, maintaining a consistent source 
of streptavidin fluorochrome, a consistent streptavidin–biotin 
ratio, and a consistent tetramer concentration in the staining 
reaction.
optimizing Fluorochromes  
and gating strategy
Tetramer intensity varies with the tetramerization procedure 
(Figure  2A), and streptavidin-PE intensity varies somewhat 
depending on the manufacturer (data not shown). Therefore, 
when comparisons are required, it is important to standardize 
these parameters for the entire study and for all laboratories 
involved. Furthermore, after construction from monomers, 
tetramers will lose integrity after 2–3  months. Therefore, it is 
important to calculate the assay time required for a batch of clini-
cal samples so that they can be analyzed with a single monomer 
batch. The brightest signal relative to background will be obtained 
with streptavidin conjugated to fluorochromes such as PE, APC, 
or Brilliant Violet (BV) 421. We have successfully combined 
tetramers of different pMHC specificities conjugated to BV421 
and PE, respectively to identify single or double labeling, i.e., 
to determine TCR cross-reactivity (6). Reduction in myeloid 
cell background is avoided with the use of Fc block, live/dead 
and lineage exclusion gating, and optimization of CD3 and CD4 
staining to ensure tight T cell gating, with, minimal background 
staining of CD3+ CD4− T cells. Figure 3 is an example of the gat-
ing strategy. For cell surface staining, we avoid the use of tandem 
dyes based on PE, which could degrade and give false positive PE 
signal in the tetramer-PE channel. Staining and tetramerization 
protocols are provided in Supplementary Material.
dIsCUssIoN
As a result of advances in antigen-specific immunotherapeutic 
approaches to induce tolerance, such as the delivery of antigen-
exposed tolerogenic dendritic cells or other forms of antigen 
delivery designed to promote tolerance, early-stage translation 
to clinical trials in autoimmune disease has begun (1, 19–22). 
While animal data are promising, it is likely that for consistent 
demonstration of robust clinical outcomes from antigen-specific 
approaches, ongoing basic and clinical development from a num-
ber of angles will be required. During the current exploratory 
phase in this field, it is essential to gather as much information 
as possible on the CD4+ T cells responding to delivered antigen 
to assess and to improve on the outcomes of clinical trials of 
antigen-specific immunomodulatory approaches. pMHCII 
multimers represent an excellent tool to monitor antigen-specific 
CD4+ T  cell responses, as they can be used to quantify the 
frequency and assess the phenotype of antigen-specific T  cells 
(6, 14). In addition, as staining reagents, they can facilitate in-
depth, exploratory single cell analyses, such as TCR sequencing, 
transcriptomics, assessment of oligoclonal expansion, and clon-
ing (6, 23). Furthermore, because they can be applied to flow 
cytometry or cell sorting, multimers are much more sensitive and 
versatile than ex vivo analyses such as ELISPOT, which struggle to 
detect low level cytokine responses above background produced 
by autoantigen-specific memory T cells (24–26).
However, due to the low avidity and high off-rate between 
pMHCII and the TCR, these assays are technically challenging for 
use in clinical trials. Here, we investigated reagent and assay limi-
tations that could impact the use of peptide–HLA–DR tetramers 
in clinical trial settings for immunomonitoring. We describe a 
peptide–MHC class II flow cytometry-based assay to quantify 
and phenotype antigen-specific CD4+ T cells. We show that this 
assay can be used in frozen PBMC, but that optimal cell yield for 
identification of antigen-specific CD4+ T cells after thawing is best 
achieved by reducing staining time before analysis on the flow 
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or HLA-DRB1*14:02-Vimentin59–71Cit64, but not HLA-
DRB1*14:02-CLIP (6). These studies indicate that autoantigen-
specific cells can be identified, cloned and characterized for 
peptide specificity and cross-reactivity using the methods 
described here for pMHCII staining.
Even though the described modifications resulted in repro-
ducible identification of self-antigen-specific CD4+ T cells, there 
are limitations to tetramer assays apart from the low cell frequen-
cies identified by staining. Due to the low avidity between self-
antigen–MHCII complexes and TCRs, the mean fluorescence 
intensity of tetramer staining is low. As a result background and 
positive staining tend to merge—hence attempts to amplify stain-
ing signal with dasatinib and sandwich stains—which creates 
difficulty in setting the cutoff for positive staining. This is much 
less of a problem for tetramers of higher avidity, e.g., pMHCI 
tetramers, HLA–DQ–gliadin peptide tetramers, or tetramers 
for B  cell receptor staining. To determine the cutoff between 
background and positive staining of autoantigen-specific CD4 
tetramers, we have used FMO gating. This is because control pep-
tide tetramers typically identify T cells with low-avidity staining 
to the control peptide and mismatched HLA tetramers typically 
FIgURe 3 | Gating strategy for tetramer analysis. Live cells were gated using forward and side scatter. Subsequently, single cells were gated using forward scatter 
height and area followed by side scatter height and area (upper panels). Live CD3+ cells were gated using Lineage/LIVE/DEAD marker negative and CD3-positive 
cells. Next, CD4+ T cells were gated by gating on the CD3+ CD4+ double-positive cells. The FMO sample was used to determine the tetramer-positive gate. The 
gate was set on the CD4-postive cells that are negative in the tetramer channel (middle panels). This gate was used to identify the CD4+ tetramer+ cells in the rest  
of the samples (bottom panels). Representative of 40 experiments.
cytometer. Elimination of dasatinib and sandwich amplification 
steps, combining staining steps, reducing the number of washes, 
adding DNAse during thawing, and resting of the cells after thaw-
ing all improved efficiency of identification of tetramer+ CD4+ 
T cells. As a result of these modifications, replicates of the same 
tetramer stain on the same sample showed good reproducibility 
of cell frequency (Figure 2B). Furthermore, to optimize the num-
ber of tetramer-positive cells detected, the source of monomers 
and the tetramerization formula must also be taken into account, 
as this will affect the staining outcome. When tetramerized 
similarly from biotinylated monomers and stained at the same 
concentration, replicates of the same samples stained with tetram-
ers from different sources also showed good reproducibility. 
Furthermore, we provide an example of gating strategy and tips 
on fluorochrome use. Previously we have demonstrated by single 
cell sorting using pMHCII multimers that HLA-DRB1*14:02-
Vimentin59–71+ and HLA-DRB1*14:02-Vimentin59–71Cit64+ 
autoreactive T  cells are oligoclonally expanded in the blood 
of RA patients, and that a representative HLA-DRB1*14:02-
Vimentin59–71-reactive TCR cloned from the identified sequences 
could be restimulated with HLA-DRB1*14:02-Vimentin59–71 
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